Tafalgie Therapeutics secured €12 million in a Series A funding round with Bpifrance and the EIC FUnd
04 September 2025
04 September 2025
Total investments received (USD): 13.98M
Company: Tafalgie Therapeutics
Related deals
May health in a €10M series B extension led by Nexpring Health, joined by existing shareholders Sofinnova Partners, Bpifrance, and Trill Impact.
Investments
02 March 2026
Lifeaz in a €13M series A round with Mutuelles Impact, BNP Paribas, GO CAPITAL, and Mirova, an affiliate of Natixis
Investments
01 February 2026
4Moving Biotech raised a €12 million financing with 4P-Pharma, Fondation Arthritis, SATT Lutech, Business Angels, Family Offices in France
Investments
17 January 2026
Apmonia Therapeutics raised €10M series A with Capital Grand Est, Finovam Gestion, Fondation Fournier-Majoie, Angels Santé, Capital Cell in France
Investments
09 January 2026
ErVimmune raised €17 million Series A financing with Seventure and SPRIM Global
Investments
06 January 2026
Netherlands
Austria
Germany
Switzerland
Denmark
Estonia
Finland
Iceland
Latvia
Lithuania
Norway
Ireland
Italy
Portugal
United Kingdom